
TY  - JOUR
TI  - Poster Session II: October 1 (12pm) - October 2
JO  - Journal of Neurochemistry
VL  - 123
IS  - s1
SN  - 0022-3042
UR  - https://doi.org/10.1111/j.1471-4159.2012.07906.x
DO  - doi:10.1111/j.1471-4159.2012.07906.x
SP  - 89
EP  - 128
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Neurourology and Urodynamics
JA  - Neurourology and Urodynamics
VL  - 37
IS  - S1
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.23524
DO  - doi:10.1002/nau.23524
SP  - S518
EP  - S699
PY  - 2018
ER  - 

TY  - JOUR
TI  - Subspeciality: Cardiovacular medicine
JO  - European Journal of Clinical Investigation
VL  - 31
IS  - s1
SN  - 0014-2972
UR  - https://doi.org/10.1111/j.1365-2362.2001.00001.x
DO  - doi:10.1111/j.1365-2362.2001.00001.x
SP  - 1
EP  - 44
PY  - 2001
ER  - 

TY  - JOUR
TI  - Abstracts of the IPITA-IXA-CTS 2015 Joint Congress November 15–19, 2015, Melbourne, Australia
JO  - Xenotransplantation
JA  - Xenotransplantation
VL  - 22
IS  - S1
SN  - 0908-665X
UR  - https://doi.org/10.1111/xen.12206
DO  - doi:10.1111/xen.12206
SP  - S121
EP  - S184
PY  - 2015
ER  - 

TY  - JOUR
AU  - Sousa, Bruna R.
AU  - Parreira, Ricardo C.
AU  - Fonseca, Emerson A
AU  - Amaya, Maria J.
AU  - Tonelli, Fernanda M. P.
AU  - Lacerda, Samyra M. S. N.
AU  - Lalwani, Pritesh
AU  - Santos, Anderson K.
AU  - Gomes, Katia N.
AU  - Ulrich, Henning
AU  - Kihara, Alexandre H.
AU  - Resende, Rodrigo R.
TI  - Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications
JO  - Cytometry Part A
JA  - Cytometry
VL  - 85
IS  - 1
SN  - 1552-4922
UR  - https://doi.org/10.1002/cyto.a.22402
DO  - doi:10.1002/cyto.a.22402
SP  - 43
EP  - 77
KW  - umbilical cord blood
KW  - bone marrow
KW  - adipose-derived
KW  - placental and amniotic fluid
KW  - menstrual blood stem cells
KW  - differentiation
PY  - 2014
AB  - Abstract Stem cells are known for their capacity to self-renew and differentiate into at least one specialized cell type. Mesenchymal stem cells (MSCs) were isolated initially from bone marrow but are now known to exist in all vascularized organ or tissue in adults. MSCs are particularly relevant for therapy due to their simplicity of isolation and cultivation. The International Society for Cellular Therapy (ISCT) has proposed a set of standards to define hMSCs for laboratory investigations and preclinical studies: adherence to plastic in standard culture conditions; in vitro differentiation into osteoblasts, adipocytes, and chondroblasts; specific surface antigen expression in which ≥95% of the cells express the antigens recognized by CD105, CD73, and CD90, with the same cells lacking (≤2% positive) the antigens CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR. In this review we will take an historical overview of how umbilical cord blood, bone marrow, adipose-derived, placental and amniotic fluid, and menstrual blood stem cells, the major sources of human MSC, can be obtained, identified and how they are being used in clinical trials to cure and treat a very broad range of conditions, including heart, hepatic, and neurodegenerative diseases. An overview of protocols for differentiation into hepatocytes, cardiomyocytes, neuronal, adipose, chondrocytes, and osteoblast cells are highlighted. We also discuss a new source of stem cells, induced pluripotent stem cells (iPS cells) and some pathways, which are common to MSCs in maintaining their pluripotent state. ? 2013 International Society for Advancement of Cytometry
ER  - 

TY  - JOUR
TI  - International Symposium on Cell Signaling—from Disease to Drug Discovery
JO  - Cell Biology International
VL  - 25
IS  - 10
SN  - 1065-6995
UR  - https://doi.org/10.1006/cbir.2001.0808
DO  - doi:10.1006/cbir.2001.0808
SP  - 1037
EP  - 1077
PY  - 2001
ER  - 

TY  - JOUR
TI  - 9TH ECE PROCEEDINGS
JO  - Epilepsia
VL  - 51
IS  - s4
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2010.02658.x
DO  - doi:10.1111/j.1528-1167.2010.02658.x
SP  - 1
EP  - 189
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 17
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14306
DO  - doi:10.1111/ajt.14306
SP  - 411
EP  - 815
PY  - 2017
ER  - 

TY  - JOUR
TI  - XVIII International Congress of Neuropathology September 15, 2014
JO  - Brain Pathology
JA  - Brain Pathology
VL  - 24
IS  - S1
SN  - 1015-6305
UR  - https://doi.org/10.1111/bpa.12183_2
DO  - doi:10.1111/bpa.12183_2
SP  - 2
EP  - 14
PY  - 2014
ER  - 

TY  - JOUR
TI  - POSTER DISCUSSION SESSIONS
JO  - Allergy
VL  - 63
IS  - s88
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2008.01759.x
DO  - doi:10.1111/j.1398-9995.2008.01759.x
SP  - 78
EP  - 157
PY  - 2008
ER  - 

TY  - JOUR
TI  - Editorial board - TOC
JO  - Human Brain Mapping
JA  - Hum. Brain Mapp.
VL  - 38
IS  - 7
SN  - 1065-9471
UR  - https://doi.org/10.1002/hbm.23385
DO  - doi:10.1002/hbm.23385
SP  - 3317
EP  - 3321
PY  - 2017
ER  - 

TY  - JOUR
TI  - RESEARCH PODIUM ABSTRACTS
JO  - Value in Health
VL  - 12
IS  - 7
SN  - 1098-3015
UR  - https://doi.org/10.1111/j.1524-4733.2009.00592_1.x
DO  - doi:10.1111/j.1524-4733.2009.00592_1.x
SP  - A221
EP  - A237
PY  - 2009
ER  - 

TY  - JOUR
AU  - du Souich, Patrick
AU  - García, Antonio G.
AU  - Vergés, Josep
AU  - Montell, Eulàlia
TI  - Immunomodulatory and anti-inflammatory effects of chondroitin sulphate
JO  - Journal of Cellular and Molecular Medicine
VL  - 13
IS  - 8a
SN  - 1582-1838
UR  - https://doi.org/10.1111/j.1582-4934.2009.00826.x
DO  - doi:10.1111/j.1582-4934.2009.00826.x
SP  - 1451
EP  - 1463
KW  - chondroitin sulphate
KW  - inflammation
KW  - autoimmune diseases
KW  - psoriasis
KW  - atherosclerosis
KW  - inflammatory bowel disease
KW  - Alzheimer's disease
KW  - Parkinson disease
KW  - multiple sclerosis
PY  - 2009
AB  - Abstract ?? Biochemistry of chondrotin sulphate ?? Mechanism of action of chondroitin sulphate -? Effect of chondroitin sulphate on the chondrocyte -? Effect of chondroitin sulphate on the synovial membrane -? Effect of chondroitin sulphate on subchondral bone ?? Human use of chondroitin sulphate -? Chondrotin sulphate in osteoarthritis -? Chondrotin sulphate in psoriasis -? Chondrotin sulphate in atherosclerosis -? Chondroitin sulphate in IBD -? Chondroitin sulphate in degenerative diseases of the central nervous system (CNS) -? Other autoimmune diseases that may benefit from chondroitin sulphate ?? Conclusions Chondroitin sulphate (CS) is a natural glycosaminoglycan present in the extracellular matrix and is formed by the 1?3 linkage of D-glucuronic acid to N-acetylgalactosamine. In chondrocytes, CS diminishes interleukin-1 p (IL-1p)-induced increases in p38 mitogen-activated protein kinase (p38MAPK) and signal-regulated kinase 1/2 (Erk1/2) phosphorylation, and decreases nuclear factor-KB (NF-kB) nuclear translocation and as a consequence, reduces the formation of pro-inflammatory cytokines, IL-1 p and TNF-a, and pro-inflammatory enzymes, such as phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2) and nitric oxide synthase-2 (NOS-2). The mechanism of action of CS explains its beneficial effect on the cartilage, synovial membrane and subchondral bone. On the other hand, in vivo, CS given orally prevents hepatic NF-kB nuclear translocation, suggesting that systemic CS may elicit an anti-inflammatory effect in many tissues besides the articulation. There is preliminary evidence showing that in human beings, CS may be of benefit in other diseases where inflammation is an essential marker, such as psoriasis and atherosclerosis. The review of the literature suggest that CS might also be of interest for the treatment of other diseases with an inflammatory and/or autoimmune character, such as inflammatory bowel disease, degenerative diseases of the central nervous system and stroke, multiple sclerosis and other autoimmune diseases.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
VL  - 3
IS  - s1
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2005.0300g.x
DO  - doi:10.1111/j.1538-7836.2005.0300g.x
SP  - SYM01
EP  - SYM90
PY  - 2005
ER  - 

TY  - JOUR
TI  - Symposia
JO  - The FEBS Journal
VL  - 276
IS  - s1
SN  - 1742-464X
UR  - https://doi.org/10.1111/j.1742-4658.2009.07046.x
DO  - doi:10.1111/j.1742-4658.2009.07046.x
SP  - 5
EP  - 84
PY  - 2009
ER  - 

TY  - JOUR
TI  - The Winter Scientific Meeting (191st) (incorporating the Trainees' Programme) of the Pathological Society of Great Britain and Ireland. 3 – 5 January 2007. Hosted by the Department of Pathology, Royal Free and University College Medical School, London.
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 211
IS  - S1
SN  - 0022-3417
UR  - https://doi.org/10.1002/path.2166
DO  - doi:10.1002/path.2166
SP  - 1A
EP  - 29A
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Artificial Organs
VL  - 31
IS  - 10
SN  - 0160-564X
UR  - https://doi.org/10.1111/j.1525-1594.2007.00491.x
DO  - doi:10.1111/j.1525-1594.2007.00491.x
SP  - A33
EP  - A100
PY  - 2007
ER  - 

TY  - JOUR
TI  - RESEARCH POSTER ABSTRACTS
JO  - Value in Health
VL  - 12
IS  - 7
SN  - 1098-3015
UR  - https://doi.org/10.1111/j.1524-4733.2009.00592_2.x
DO  - doi:10.1111/j.1524-4733.2009.00592_2.x
SP  - A237
EP  - A460
PY  - 2009
ER  - 

TY  - JOUR
AU  - Yao, Min
AU  - Galanopoulos, Nicholas
AU  - Lavertu, Pierre
AU  - Fu, Pingfu
AU  - Gibson, Michael
AU  - Argiris, Athanassios
AU  - Rezaee, Rod
AU  - Zender, Chad
AU  - Wasman, Jay
AU  - Machtay, Mitchell
AU  - Savvides, Panos
TI  - Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck
JO  - Head & Neck
JA  - Head Neck
VL  - 37
IS  - 11
SN  - 1043-3074
UR  - https://doi.org/10.1002/hed.23813
DO  - doi:10.1002/hed.23813
SP  - 1665
EP  - 1671
KW  - head and neck cancer
KW  - radiation
KW  - bevacizumab
KW  - docetaxel
KW  - chemoradiation
PY  - 2015
AB  - Abstract Background The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m2) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy. ? 2014 Wiley Periodicals, Inc. Head Neck 37: 1665?1671, 2015
ER  - 

TY  - JOUR
TI  - Day at a Glance
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6135.2004.00492.x
DO  - doi:10.1111/j.1600-6135.2004.00492.x
SP  - 51
EP  - 159
PY  - 2004
ER  - 
